Strategic Initiative

Slingshot members are tracking this corporate initiative:

Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Janssen Biotech has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC). The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of Janssen’s investigational immunotherapy JNJ-64041757 and Bristol-Myer Squibb’s PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), in NSCLC patients.JNJ-64041757 is an antigen-presentation therapeutic, based on Live Attenuated Double-Deleted (LADD) Listeria monocytogenes strains engineered to induce an immune response against NSCLC tumors.  Janssen licensed JNJ-64041757 (previously referred to as ADU-214) and another compound, JNJ-64041809 (previously referred to as ADU-741), from Aduro Biotech, Inc., in 2014. Both are currently in Phase 1 clinical development: JNJ-64041757 in lung cancer and JNJ-64041809 in prostate cancer.  OPDIVO is indicated for the treatment of patients with NSCLC with progression on or after platinum-based chemotherapy.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jul 26, 2016
Projected Implementation:
Q3, 2016
Relevance Tracked Until:
Q4, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Antigen-presentation Therapeutic, Jnj-64041757, Prostate Cancer, Opdivo, Non-small Cell Lung Cancer, Jnj-64041809, Listeria Monocytogenes, Adu-214, Adu-741, Pd-1 Immune Checkpoint Inhibitor, Nivolumab